GENENTECH, INC.
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1976-01-01
- Employees
- 11.1K
- Market Cap
- -
- Website
- http://www.gene.com
A Study of the Efficacy and Safety of Omalizumab Through 48 Weeks in Participants With Chronic Idiopathic Urticaria
- First Posted Date
- 2015-03-19
- Last Posted Date
- 2018-03-29
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 206
- Registration Number
- NCT02392624
- Locations
- 🇺🇸
Florida Ctr-Allergy & Asthma, Miami, Florida, United States
🇺🇸James Q. Del Rosso, DO, LLC, Las Vegas, Nevada, United States
🇺🇸Allergy & Asthma Research Center, San Antonio, Texas, United States
A Phase I Bioavailability and Pharmacokinetic Study of [14C]-Ipatasertib Single Oral and Intravenous Doses in Healthy Male Subjects
- Conditions
- Interventions
- First Posted Date
- 2015-03-17
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT02390492
A Study of Crenezumab in Participants With Mild to Moderate Alzheimer Disease
- Conditions
- Interventions
- First Posted Date
- 2015-02-03
- Last Posted Date
- 2019-07-24
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 77
- Registration Number
- NCT02353598
- Locations
- 🇺🇸
UCSF - Memory and Aging Center, San Francisco, California, United States
🇺🇸Brain Matters Research, Inc., Delray Beach, Florida, United States
🇺🇸Miami Jewish Health Systems, Miami, Florida, United States
A Study of Obinutuzumab + Bendamustine (BG) in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL)
- Conditions
- Interventions
- First Posted Date
- 2014-12-19
- Last Posted Date
- 2020-02-11
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 102
- Registration Number
- NCT02320487
- Locations
- 🇺🇸
Arizona Oncology Associates, PC - HOPE, Tucson, Arizona, United States
🇺🇸Cancer Care & Hematology; Specialists of Chicagoland, Niles, Illinois, United States
🇺🇸San Juan Oncology Associates, Farmington, New Mexico, United States
A Study of GDC-0927 in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer
- First Posted Date
- 2014-12-15
- Last Posted Date
- 2020-10-05
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 43
- Registration Number
- NCT02316509
- Locations
- 🇺🇸
Massachusetts General Hospital., Boston, Massachusetts, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇪🇸Hospital General Universitario Gregorio Maranon, Madrid, Spain
A Post-Marketing Study of the Immunogenicity of Somatropin (Ribosomal Deoxyribo Nucleic Acid [rDNA] Origin) Injection (Nutropin AQ®) in Children With Growth Hormone Deficiency
- First Posted Date
- 2014-12-09
- Last Posted Date
- 2019-01-08
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 82
- Registration Number
- NCT02311894
- Locations
- 🇺🇸
Barry J Reiner, MD, LLC, Baltimore, Maryland, United States
🇺🇸Endocrine Associates of Dallas, Dallas, Texas, United States
🇺🇸Miami Children's Hospital, Miami, Florida, United States
A Study of Ipatasertib (GDC-0068) in Combination With Paclitaxel as Neoadjuvant Treatment for Participants With Early Stage Triple Negative Breast Cancer
- First Posted Date
- 2014-11-26
- Last Posted Date
- 2018-10-17
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 151
- Registration Number
- NCT02301988
- Locations
- 🇪🇸
Hospital Universitario Virgen Macarena, Seville, Sevilla, Spain
🇺🇸Arizona Oncology Associates, PC-CASA, Tucson, Arizona, United States
🇺🇸Rocky Mountain Cancer Center - Lakewood (West), Lakewood, Colorado, United States
A Study to Evaluate the Pharmacokinetics and Safety of Cobimetinib in Volunteers With and Without Liver Damage
- First Posted Date
- 2014-11-24
- Last Posted Date
- 2016-02-19
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 28
- Registration Number
- NCT02300025
A Study of MHAA4549A in Combination With Oseltamivir Versus Oseltamivir in Participants With Severe Influenza A Infection
- First Posted Date
- 2014-11-18
- Last Posted Date
- 2018-06-18
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 168
- Registration Number
- NCT02293863
- Locations
- 🇲🇽
CEPREP; Hospital Universitario, Monterrey, Mexico
🇵🇱Oddział Anestezjologii i Intensywnej Terapii Wojewódzki Specjalistyczny Szpital im dr Wł Biegańsk, Łódź, Poland
🇧🇬MHAT "Dr. Tota Venkova"- Gabrovo, Gabrovo, Bulgaria
A Study of Lampalizumab Intravitreal Injections Administered Every Two Weeks or Every Four Weeks to Participants With Geographic Atrophy
- First Posted Date
- 2014-11-11
- Last Posted Date
- 2019-09-25
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 96
- Registration Number
- NCT02288559
- Locations
- 🇺🇸
Retinal Diagnostic Center, Campbell, California, United States
🇺🇸The Retina Partners, Encino, California, United States
🇺🇸Loma Linda University, Loma Linda, California, United States